An observational study in Parkinson Disease, Multiple System Atrophy, Parkinson Variant and Progressive Supranuclear Palsy, sponsored by University of Florida. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by University of Florida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.
Among the 41 studies in Parkinson Disease by University of Florida, this one is one of 8 that started in 2021, is one of 8 observational ones, and was the 35th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 40–75
University of Florida · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 21–89
University of Florida · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 45–85
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 4 1
First in 2004; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 315 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 35 across the 33 interventional studies, 30 across the 8 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
3 of the studies in Parkinson Disease by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07348705University of FloridaElectrophysiology-based DBS Programming for PD | 2027-01-15 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT06911229University of FloridaNeurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Parkinson Disease by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Adults between the ages of 40 and 80 who meet one of the three diagnoses: PD, MSAp, or PSP
*As of 11/9/23, we have filled the cohorts for both PD and PSP patients. We are only enrolling MSAp patients at this time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinically diagnosed Parkinson's disease
Diagnostic Test: AIDP
Clinically diagnosed Multiple System Atrophy, Parkinsonian variant
Diagnostic Test: AIDP
Clinically diagnosed Progressive Supranuclear Palsy
Diagnostic Test: AIDP
Machine learning algorithm of imaging data
Predicted diagnosis accuracy
utilizing the automated imaging differentiation of Parkinsonism (AIDP) tool to predict diagnosis compared to the expertise of two movement disorder specialists
Time frame: 12-18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Mar 2027, 68 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 68 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.